Dr. Sarah Tasian, MD
Claim this profileChildren's Hospital of Philadelphia
Studies Acute Myeloid Leukemia
Studies Acute Myelogenous Leukemia
5 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Sarah Tasian, MD is currently running
Diagnostic Testing
for Pediatric Leukemia
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Recruiting1 award Phase 1 & 211 criteria
Imetelstat + Chemotherapy
for Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as fludarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imetelstat in combination with fludarabine and cytarabine may work better in treating patients with refractory or recurrent AML, MDS, and JMML.
Recruiting1 award Phase 14 criteria
More about Sarah Tasian, MD
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Sarah Tasian, MD has experience with
- Cytarabine
- Fludarabine
- Matched Targeted Therapy
- Methotrexate
- Selinexor
- Venetoclax
Breakdown of trials Sarah Tasian, MD has run
Acute Myeloid Leukemia
Acute Myelogenous Leukemia
Biphenotypic Leukemia
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sarah Tasian, MD specialize in?
Sarah Tasian, MD focuses on Acute Myeloid Leukemia and Acute Myelogenous Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved treating patients, or patients who are undergoing treatment.
Is Sarah Tasian, MD currently recruiting for clinical trials?
Yes, Sarah Tasian, MD is currently recruiting for 2 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Sarah Tasian, MD has studied deeply?
Yes, Sarah Tasian, MD has studied treatments such as Cytarabine, Fludarabine, Matched Targeted Therapy.
What is the best way to schedule an appointment with Sarah Tasian, MD?
Apply for one of the trials that Sarah Tasian, MD is conducting.
What is the office address of Sarah Tasian, MD?
The office of Sarah Tasian, MD is located at: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19404 United States. This is the address for their practice at the Children's Hospital of Philadelphia.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.